Answers are grounded in this paper and cite their sources.
• Human immunodeficiency virus (HIV) is a retrovirus that infects CD4+ T-cells causing severe immunosuppression and death if left untreated. • In 2023, 39.9 million people were living with HIV globally and 630,000 people died of HIV-related disease. • Over 100,000 people accessed HIV care in England in 2023, a year-on-year increase from 2020. • HIV mortality has been driven down very successfully by antiretroviral therapy (ART): combinations of drugs with potent anti-HIV activity. People living with HIV can reach a life expectancy only slightly below the baseline population, providing they achieve a fully suppressed viral load with restored CD4 T-cell counts. Excellent adherence is essential. • Over time, ART has become better tolerated with reduced side effects and combination tablets to reduce pill burden. • Long-acting injectables and infusions offer the potential for HIV treatment and prevention without requiring patients to take daily tablets. Several of these agents are also effective against multidrug resistant HIV. These could be very useful additions to the anti-HIV armamentarium. • Continuing the progress against HIV requires sustained international funding, which has been severely threatened by recent geopolitical changes. Antiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV), from almost universally fatal into a manageable condition. With expansion of ART coverage, global HIV-related deaths have fallen by 69% since their peak in 2004. ART is highly effective at reducing HIV transmission; people with fully suppressed viral load do not transmit the virus sexually. Treatment is becoming easier, with better tolerated drugs, reduced side effects and combination tablets. Here, we review the changing landscape of HIV epidemiology and treatment, focusing on the impact of ART and the latest developments in long-acting injectable HIV therapy. These agents offer the potential for treatment and prevention without requiring patients to take daily tablets, including for multidrug resistant infections. HIV epidemic control is on the horizon for many countries due highly effective prevention programmes. However, emerging funding challenges due to geopolitical realignment is threatening the substantial gains of the last 20 years.
No takes yet. Share an insight, caveat, or question.
Dorcas Aliyu (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: